论文部分内容阅读
目的探讨使用小剂量瑞舒伐他汀联合依折麦布治疗高脂血症的疗效。方法高脂血症的患者82例,随机分为实验组(41例),给予瑞舒伐他汀联合依折麦布治疗,对照组(41例),给予瑞舒伐他汀治疗,2个月后观察两组临床疗效及治疗前后肝功[谷丙转氨酶(ALT),谷草转氨酶(AST)]变化。结果小剂量瑞舒伐他汀联合依折麦布可显著降低血清总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C),使高密度脂蛋白胆固醇(HDL-C)明显提升,治疗前后比较差异有统计学意义(P<0.05);对照组和实验组组间比较差异有统计学意义(P<0.05)。对照组和实验组治疗前后ALT、AST比较无明显升高,两组间比较,差异无统计学意义(P>0.05)。结论小剂量瑞舒伐他汀联合依折麦布可以达到强化降脂的作用,较单独应用瑞舒伐他汀疗效显著,而且不增加肝毒性。
Objective To investigate the efficacy of low dose rosuvastatin combined with ezetimibe in the treatment of hyperlipidemia. Methods Eighty-two patients with hyperlipidemia were randomly divided into experimental group (n = 41), rosuvastatin combined with ezetimibe, and control group (n = 41). Rosuvastatin was given to the patients. After two months The clinical curative effect and changes of liver function [ALT, AST] before and after treatment were observed. Results Low dose of rosuvastatin combined with ezetimibe significantly reduced serum TC, TG and LDL-C, ) Was significantly improved before and after treatment, the difference was statistically significant (P <0.05); control group and experimental group, the difference was statistically significant (P <0.05). There was no significant difference in ALT and AST between the control group and the experimental group before and after treatment. There was no significant difference between the two groups (P> 0.05). Conclusions Low-dose rosuvastatin combined with ezetimibe can enhance lipid-lowering effect, which is more effective than rosuvastatin alone and does not increase hepatotoxicity.